About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in a specific subset of macrophages), plays a key role in immunotherapy resistance. Blocking HPGDS may be a new way to overcome immunotherapy resistance in melanoma patients and potentially in other tumors facing similar challenges. The results of this study were published in Cancer Discovery.
2025
Breakthrough paves way for predicting melanoma patient response to treatment
A major step forward has been made in predicting how well melanoma patients would respond to treatment, thanks to world-leading University of Otago – ?t?kou Whakaihu Waka research.
Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors
Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors
Melanoma’s Hidden Toll in Skin of Color
ATHENS, Greece — Although melanoma occurs much more frequently in people with lighter complexions, people with darker skin are also at risk, according to experts who spoke at the 11th World Congress of Melanoma and 21st EADO Congress 2025 on the challenges of diagnosing the condition in patients with dark skin.